-
公开(公告)号：US20120288534A1
公开(公告)日：2012-11-15
申请号：US13422994
申请日：2012-03-16
申请人： Neil Bodick , Robert C. Blanks , Anjali Kumar , Michael D. Clayman , Mark Moran
发明人： Neil Bodick , Robert C. Blanks , Anjali Kumar , Michael D. Clayman , Mark Moran
CPC分类号： A61K31/58 , A61K9/0019 , A61K9/0024 , A61K9/14 , A61K9/1641 , A61K9/1647 , A61K9/1694 , A61K31/573 , A61K47/34
摘要： Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
摘要翻译： 提供皮质类固醇微粒制剂用于治疗疼痛，包括由炎症性疾病如骨关节炎或类风湿性关节炎引起的疼痛，以及用于减缓，阻止或逆转由炎性疾病引起的组织的结构损伤，例如关节和/或周围的损伤 由骨关节炎或类风湿关节炎引起的关节组织。 局部施用皮质类固醇微粒制剂作为持续释放剂型（具有或不具有立即释放组分），其导致功效伴随着对内源性皮质醇产生的临床上不显着或无可测量的影响。
-
公开(公告)号：US20120282298A1
公开(公告)日：2012-11-08
申请号：US13368580
申请日：2012-02-08
申请人： Neil Bodick , Robert C. Blanks , Anjali Kumar , Michael D. Clayman , Mark Moran
发明人： Neil Bodick , Robert C. Blanks , Anjali Kumar , Michael D. Clayman , Mark Moran
CPC分类号： A61K31/58 , A61K9/0019 , A61K9/0024 , A61K9/14 , A61K9/1641 , A61K9/1647 , A61K9/1694 , A61K31/573 , A61K47/34
摘要： Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
摘要翻译： 提供皮质类固醇微粒制剂用于治疗疼痛，包括由炎症性疾病如骨关节炎或类风湿性关节炎引起的疼痛，以及用于减缓，阻止或逆转由炎性疾病引起的组织的结构损伤，例如关节和/或周围的损伤 由骨关节炎或类风湿关节炎引起的关节组织。 局部施用皮质类固醇微粒制剂作为持续释放剂型（具有或不具有立即释放组分），其导致功效伴随着对内源性皮质醇产生的临床上不显着或无可测量的影响。
-
3.发明申请公开(公告)号：US20150050338A1
公开(公告)日：2015-02-19
申请号：US14466089
申请日：2014-08-22
IPC分类号： A61K31/353 , A61K36/47 , A61K9/28
CPC分类号： A61K31/353 , A61K9/28 , A61K31/365 , A61K31/426 , A61K36/38 , A61K36/47
摘要： The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
摘要翻译： 本发明提供了治疗腹泻型肠易激综合征综合征的方法，其包括向有需要的患者施用足以治疗腹泻型肠易激综合征（d-IBS）的氯离子转运抑制剂。 d-IBS的治疗包括治疗d-IBS的腹泻成分以及与d-IBS相关的疼痛，腹部不适和其他症状。 在一个实施方案中，氯离子转运抑制剂是疏水剂。
-
公开(公告)号：US08828440B2
公开(公告)日：2014-09-09
申请号：US13422994
申请日：2012-03-16
申请人： Neil Bodick , Robert C. Blanks , Anjali Kumar , Michael D. Clayman , Mark Moran
发明人： Neil Bodick , Robert C. Blanks , Anjali Kumar , Michael D. Clayman , Mark Moran
CPC分类号： A61K31/58 , A61K9/0019 , A61K9/0024 , A61K9/14 , A61K9/1641 , A61K9/1647 , A61K9/1694 , A61K31/573 , A61K47/34
摘要： Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
摘要翻译： 提供皮质类固醇微粒制剂用于治疗疼痛，包括由炎症性疾病如骨关节炎或类风湿性关节炎引起的疼痛，以及用于减缓，阻止或逆转由炎性疾病引起的组织的结构损伤，例如关节和/或周围的损伤 由骨关节炎或类风湿关节炎引起的关节组织。 局部施用皮质类固醇微粒制剂作为持续释放剂型（具有或不具有立即释放组分），其导致功效伴随着对内源性皮质醇产生的临床上不显着或无可测量的影响。
-
公开(公告)号：US20070254050A1
公开(公告)日：2007-11-01
申请号：US11510152
申请日：2006-08-24
IPC分类号： A61K36/47 , A61K31/426 , A61K31/365
CPC分类号： A61K31/353 , A61K9/28 , A61K31/365 , A61K31/426 , A61K36/38 , A61K36/47
摘要： The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
摘要翻译： 本发明提供了治疗腹泻型肠易激综合征综合征的方法，其包括向有需要的患者施用足以治疗腹泻型肠易激综合征（d-IBS）的氯离子转运抑制剂。 d-IBS的治疗包括治疗d-IBS的腹泻成分以及与d-IBS相关的疼痛，腹部不适和其他症状。 在一个实施方案中，氯离子转运抑制剂是疏水剂。
-
6.发明申请公开(公告)号：US20120189720A1
公开(公告)日：2012-07-26
申请号：US13304604
申请日：2011-11-25
IPC分类号： A61K31/353 , A61P1/00 , A61P25/00 , A61K36/185 , A61K36/47
CPC分类号： A61K31/353 , A61K9/28 , A61K31/365 , A61K31/426 , A61K36/38 , A61K36/47
摘要： The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
摘要翻译： 本发明提供了治疗腹泻型肠易激综合征综合征的方法，其包括向有需要的患者施用足以治疗腹泻型肠易激综合征（d-IBS）的氯离子转运抑制剂。 d-IBS的治疗包括治疗d-IBS的腹泻成分以及与d-IBS相关的疼痛，腹部不适和其他症状。 在一个实施方案中，氯离子转运抑制剂是疏水剂。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.023 秒)
